BerGenBio: How EMT inhibitors aim to combat drug-resistant Cancer




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BerGenBio: How EMT inhibitors aim to combat drug-resistant Cancer
Released on: January 08, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Richard Godfrey, CEO of BerGenBio discusses how their pipeline of EMT inhibitors disrupt mechanisms of acquired drug resistance, aiding drug sensitivity in aggressive and metastatic cancers.
  • Summary
  • Transcript
  • Company
Richard Godfrey, CEO of BerGenBio discusses how their pipeline of EMT inhibitors disrupt mechanisms of acquired drug resistance, aiding drug sensitivity in aggressive and metastatic cancers.
Richard Godfrey, CEO of BerGenBio discusses how their pipeline of EMT inhibitors disrupt mechanisms of acquired drug resistance, aiding drug sensitivity in aggressive and metastatic cancers.
BerGenBio
BerGenBio AS is a privately-held biotech company focused on developing novel therapeutics for metastatic and drug resistant cancers by targeting the epithelial to mesenchymal transition (EMT) process in cancer cells. The EMT is a process in which epithelial cells undergo multiple phenotypic changes that enhance their migratory capacity, invasiveness and resistance to apoptosis. The Company’s lead program BGB324 which is due to enter Phase I clinical trials in Q1/2013, is a novel, orally bioavailable inhibitor of Axl kinase, a key target in the EMT process and associated with drug resistance and poor prognosis in a a number of cancer types . BerGenBio is discovering novel targets in the EMT area through its proprietary CellSelect technology, which is a powerful target discovery and validation tool providing greater biological insight to the role and function of targets and illustrates their potential for therapeutic benefit through regulated dose response therapeutic-mimetic studies of target inhibition and translational preclinical modeling. The technology is also used in identification and validation of pharmacodynamic markers, a key part of the company’s clinical development strategy for its programs. Based on this technology, the Company is building a pipeline of novel validated targets in the EMT arena for different cancer indications. The Company was spun out of University of Bergen in Norway, by Professor Jim Lorens, a thought leader in the field of EMT and cancer stem cells and Dr David Micklem, who developed the CellSelect target discovery and validation technology. The Company has raised significant funds from a syndicate of Norwegian investors. With its headquarters in Bergen Norway, BerGenBio has established a fully integrated research and development infrastructure that discovers and validates novel drug targets of EMT and rapidly develops therapeutics against these. With a profound understanding of cancer biology and unique target validation data the company is able to establish leadership status in the EMT and cancer stem cell area providing first-in-class therapeutics for hard to treat cancers.